A Study to Assess the Safety and Tolerability of E2511 in Healthy Participants
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT04547361
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
- Conditions
- Early Preclinical Alzheimer's DiseasePreclinical Alzheimer's Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2025-01-01
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 1400
- Registration Number
- NCT04468659
- Locations
- 🇺🇸
University of Alabama, Birmingham, Birmingham, Alabama, United States
🇺🇸Banner Alzheimer's Institute, Phoenix, Arizona, United States
🇺🇸Banner Sun Health Research Institute, Sun City, Arizona, United States
Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies
- Conditions
- Epilepsies, MyoclonicDrug Resistant Epilepsy
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- Eisai Inc.
- Registration Number
- NCT04457687
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸David Geffen School of Medicine, UCLA Mattel Children's Hospital, Los Angeles, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- Conditions
- Solid Tumor
- Interventions
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 142
- Registration Number
- NCT04300556
- Locations
- 🇺🇸
Chattanooga's Program In Women's Oncology, Chattanooga, Tennessee, United States
🇺🇸Arizona Clinical Research Center - Hunt - PPDS, Tucson, Arizona, United States
🇺🇸University of Arkansas For Medical Sciences, Little Rock, Arkansas, United States
A Study to Determine the Signs and Symptoms That Impact Daily Life of Participants With Irregular Sleep-Wake Rhythm Disorder
- Conditions
- Irregular Sleep Wake Rhythm Disorder
- Interventions
- Other: Non-interventional
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2020-10-27
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT04300569
- Locations
- 🇺🇸
ATP Clinical Research, Costa Mesa, California, United States
🇺🇸Pacific Research Network Inc, San Diego, California, United States
🇺🇸Panax Clinical Research, Miami Lakes, Florida, United States
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer
- Conditions
- Genes, Erbb-2Breast NeoplasmsReceptors, Estrogen
- Interventions
- Drug: H3B-6545 (150, 300, 450 mg)
- First Posted Date
- 2020-02-27
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT04288089
- Locations
- 🇬🇧
Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
🇺🇸Saint Luke's Cancer Institute, Kansas City, Missouri, United States
🇬🇧Sarah Cannon Research Institute UK - SCRI, London, United Kingdom
A Study to Assess Safety, Tolerability, Pharmacokinetics (PK), Immunogenicity, and Pharmacodynamics (PD) of Intravenous Infusions of E2814 in Healthy Participants
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT04231513
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
🇺🇸California Clinical Trials Medical Group/Parexel International, Glendale, California, United States
A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma
- First Posted Date
- 2019-11-06
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 81
- Registration Number
- NCT04154189
- Locations
- 🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101
- First Posted Date
- 2019-10-30
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04144140
- Locations
- 🇺🇸
University of Pittsburgh Medical Center and Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102
- First Posted Date
- 2019-09-30
- Last Posted Date
- 2020-12-14
- Lead Sponsor
- Eisai Inc.
- Registration Number
- NCT04109092
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸UCLA, Santa Monica, California, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States